Pharmacology 514:
Current Topics in Pharmacology
Journal Club

Announcements

Schedule

Faculty

Instructions for
Speakers

JClub Archive

Current Topics in Pharmacology
Phcol 514
12:30 PM, Wednesday, January 18, 2000
Room T-530/530A HSC

Speaker: Scott Auerbach
Topic: VHL: A Tumor Suppressor Like No Other

References:

  1. Kibel, A., Iliopoulos, O., DeCaprio, J.A., and Kaelin, W.G., Jr. (1995). Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C [see comments]. Science 269, 1444-1446.

  2. Duan, D.R., Pause, A., Burgess, W.H., Aso, T., Chen, D.Y., Garrett, K.P., Conaway, R.C., Conaway, J.W., Linehan, W.M., and Klausner, R.D. (1995). Inhibition of transcription elongation by the VHL tumor suppressor protein [see comments]. Science 269, 1402-1406.

  3. Lonergan, K.M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R.C., Conaway, J.W., and Kaelin, W.G., Jr. (1998). Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell Biol. 18, 732-741.

  4. Stebbins, C.E., Kaelin, W.G., Jr., and Pavletich, N.P. (1999). Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455-461.

  5. Pause, A., Peterson, B., Schaffar, G., Stearman, R., and Klausner, R.D. (1999). Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc. Natl. Acad. Sci. U. S. A 96, 9533-9538.

  6. Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W.G., Jr., Conaway, R.C., and Conaway, J.W. (1998). The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12, 3872-3881.

  7. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature 399 , 271-275.

  8. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M., and Krek, W. (1999). The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13 , 1822-1833.

Reviews:

  1. Kaelin,W.G., Jr. (1999). Cancer. Many vessels, faulty gene [news; comment]. Nature 399, 203-204.

  2. Tyers, M. and Rottapel, R. (1999). VHL: a very hip ligase [comment]. Proc. Natl. Acad. Sci. U. S. A 96, 12230-12232.

  3. Zbar, B., Kaelin, W., Maher, E., and Richard, S. (1999). Third International Meeting on von Hippel-Lindau disease. Cancer Res. 59, 2251-2253.

1999-2000 Journal Club Schedule
Other
Pharmacology
Courses

Announcements | Schedule | Faculty | Instructions for Speakers | JClub Archives